Drug intelligence / Profile preview

Enzynorm

Development stage
Unknown
Lead developer
Nordmark Arzneimittel
Modality
Recombinant Proteins and Enzymes, Small Molecules
Administration
Oral
01

Overview

Enzynorm is a fixed combination pharmaceutical product containing pepsin and betaine hydrochloride (often referred to as amino acid hydrochloride). It is primarily indicated for the treatment of functional dyspepsia and other digestive disorders associated with gastric hypoacidity (low stomach acid production). Pepsin serves as a proteolytic enzyme that initiates the breakdown of dietary proteins into smaller peptides in the stomach. Betaine hydrochloride acts as an acidifying agent, lowering the gastric pH to provide the optimal acidic environment necessary for the activation of pepsinogen into pepsin and for the subsequent enzymatic activity of pepsin. This combination helps alleviate symptoms such as bloating, postprandial fullness, and upper abdominal pain by supporting the initial stages of protein digestion in patients with impaired gastric secretion.

Brand names
EnzynormEnzynorm f
Other names
Pepsin + Amino acid hydrochloridePepsin + Betaine hydrochloride

Beyond the preview

Go deeper on Enzynorm.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enzynorm.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call